Bio/Pharma Compliance Congress on Non-Promotional Activities: Off-Label Enforcement and Emerging High-Risk Areas Needing Heightened Oversight
Melissa L. Jampol, Member of the Firm, will join a panel discussion, "Examine the Latest Trends in Off-Label Enforcement and Uncover Emerging High-Risk Areas Needing Heightened Oversight," at the Bio/Pharma Compliance Congress on Non-Promotional Activities, which runs from December 4 to 5.
Hear from stakeholders as they address the state of the industry and its impact on non-promotional activities. Topics to be discussed will include:
- Identify the latest challenges facing manufacturers
- Review recent enforcement trends and top priorities (Anti-Kickback Statute, Individual Accountability, FDA Final Guidance on Payer Communications)
- Address emerging areas of concern from federal prosecutors, legal affairs and industry
For more information, visit CBInet.com